Inside This Issue: Migraines and Related Headaches
Top News Alerts: Product Updates, Deals & Financings
Featured Company: CoLucid
Subscribe now to access over 30 articles covering developments in drugs, devices and diagnostics for the brain and nervous system.
Market Highlights: Neurotech Venture Investment Higher in 2009, Devices Reign
Venture capital investment in neurotech companies (including drugs, devices and diagnostics) gained 12.3% to $1.62 billion last year according to data compiled by NeuroInsights. Overall venture investing was down 37% to $17.7 billion, marking the lowest level since 1997, and life science investing was down 23% to $6.15 billion according to NVCA. 2009 represented a significant rebound for neurotech after only $1.44 billion in investment in 2008 - a 22% drop over the previous year. The total number of neurotech deals was essentially flat with 111 deals compared to 110 in 2008. The average neurotech deal size in gained in 2009 to $14.61 million from $13.25 million in 2008. The average life science deal size in 2009 was only $8.2 million and the overall average deal size was $6.3 million, according to NVCA data. The uptick in neurotech investment can be attributed to...
Causes and Treatments for Migraine and Related Headaches
Headaches can be a primary disorder as in migraine, cluster headache or tension headache, or a secondary symptom due to localized or systemic illness or injury. Nearly everyone has had a headache, and although headaches can be disabling, they are rarely life-threatening. Only a small minority of cases are due to serious illness. Common extracranial causes of headache include cervical spine disorders, dental problems, giant cell arteritis (temporal arteritis), glaucoma, optic neuritis, sinusitis and temporomandibular joint (TMJ) disorder. The most common systemic causes are anemia, fever, viremia (common in flu syndrome), hypertension, hypoxia and drug withdrawal. Intracranial causes are often secondary to increased intracranial pressure as a result of a space-occupying lesion such as a tumor, a hematoma, an abscess or an arterio-venous malformation. Other intracranial causes include hemorrhage, meningitis, encephalitis, vasculitis, and increased intracranial pressure resulting from benign intracranial hypertension or obstructive hydrocephalus. This article outlines drugs and devices in development for the treatment of migraines...
CoLucid: Virtual Neuropharma Keeps Focus on Clinical Development of Migraine Lead
CoLucid Pharmaceuticals is a virtual drug development company founded in December 2005 in conjunction with a $16.5 million Series A. The round was led by Pappas Ventures and Domain Associates with some smaller contributions from Pearl Street Venture Fund and Triathlon Medical Ventures. Arthur Pappas of Pappas Ventures and Jesse Treu of Domain Associates joined the board of the new company. Jim White, PhD, an industry veteran who was...
Companies Covered In This Issue Include: Abbott, Addex, Alexza, Alkermes, Allergan, Amylin Pharmaceuticals, Amicus Therapeutics, Arcion Therapeutics, Arena Pharmaceuticals, AVI BioPharma, Banyan Biomarkers,, BioBehavioral Diagnostics, Boehringer Ingelheim Pharmaceuticals, Boston Scientific, Catalyst Pharmaceutical Partners, Cara Therapeutics, Capnia, CoAxia, CoLucid, Concentric Medical, Covidien, CuremarkEisai, Forest, Genentech, GSK, IntelGenx, Jazz Pharmaceuticals, Kowa, Labopharm, Leptos Biomedical,, MAP Pharma, MedAvante, MicroTransponder, Medtronic, Natilus Neuroscience, Naurex, Neuralieve, Neuraltus Pharmaceuticals, NeoStim,, NeuroNova, NeuroSearch, NMT Medical, NuPathe, Ocera Therapeutics, Paloma Pharmaceuticals, Phosphagenics, Pozen, ProEthic, Psyadon Pharmaceuticals, QR Pharma, Raptor Pharma, ReNeuron Group, Salix Pharmaceuticals, Siemens Healthcare, Shire, Synapse Biomedical, Synosia Therapeutics, Syntropharma, Tengion, TorreyPines, Valeant, Xenoport, Watson Pharmaceuticals, Zogenix, Zynex
Subscribe Now:
|
|
